Owing to the high expression on T cell lymphoma, CD30 could be an appropriate CAR target since the toxicity of CD30 mAb therapy was attributable to the conjugated drug. This evidence concerns the gene TNFRSF8 and T-cell non-Hodgkin lymphoma.